An explainer on how oral peptide drugs are designed to survive the gut and still reach specific targets in the body. Little detail beyond the title.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A team led by IBEC with IQAC-CSIC and the University of Barcelona reports the molecule reduced the Alzheimer's-linked protein in mouse studies.
Polskie Radio covers the approval timeline for Zepbound, Eli Lilly's tirzepatide shot for weight loss. Details are thin, so tap through for the full story.
Loading…